T. Rowe Price Investment Management Inc. Sells 225,534 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)

T. Rowe Price Investment Management Inc. reduced its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 4.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,002,799 shares of the company’s stock after selling 225,534 shares during the quarter. T. Rowe Price Investment Management Inc. owned 3.10% of Neumora Therapeutics worth $53,030,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Neumora Therapeutics by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock valued at $48,466,000 after buying an additional 195,142 shares during the last quarter. Capital International Investors boosted its stake in Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock valued at $39,224,000 after purchasing an additional 3,233,179 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Neumora Therapeutics by 54.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares in the last quarter. Rock Springs Capital Management LP raised its stake in shares of Neumora Therapeutics by 15.3% in the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company’s stock worth $10,124,000 after purchasing an additional 127,005 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Neumora Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock worth $7,464,000 after purchasing an additional 5,899 shares during the last quarter. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $0.76 on Friday. Neumora Therapeutics, Inc. has a one year low of $0.62 and a one year high of $17.19. The business has a fifty day moving average price of $1.10 and a 200-day moving average price of $5.77. The firm has a market capitalization of $122.52 million, a price-to-earnings ratio of -0.41 and a beta of 2.89.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. On average, equities research analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NMRA has been the subject of several research analyst reports. William Blair downgraded Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Guggenheim cut shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. Needham & Company LLC restated a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Thursday, April 10th. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus downgraded Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $6.00 to $2.00 in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Neumora Therapeutics presently has an average rating of “Hold” and an average target price of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.